Literature DB >> 22154298

First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation.

Andreas Puschmann1, Elisabet Englund, Owen A Ross, Carles Vilariño-Güell, Sarah J Lincoln, Jennifer M Kachergus, Stephanie A Cobb, Anna-Lena Törnqvist, Stig Rehncrona, Håkan Widner, Zbigniew K Wszolek, Matthew J Farrer, Christer Nilsson.   

Abstract

The c.4309A>C mutation in the LRRK2 gene (LRRK2 p.N1437H) has recently been reported as the seventh pathogenic LRRK2 mutation causing monogenic Parkinson's disease (PD). So far, only two families worldwide have been identified with this mutation. By screening DNA from seven brains of PD patients, we found one individual with seemingly sporadic PD and LRRK2 p.N1437H mutation. Clinically, the patient had levodopa-responsive PD with tremor, and developed severe motor fluctuations during a disease duration of 19 years. There was severe and painful ON-dystonia, and severe depression with suicidal thoughts during OFF. In the advanced stage, cognition was slow during motor OFF, but there was no noticeable cognitive decline. There were no signs of autonomic nervous system dysfunction. Bilateral deep brain stimulation of the subthalamic nucleus had unsatisfactory results on motor symptoms. The patient committed suicide. Neuropathological examination revealed marked cell loss and moderate alpha-synuclein positive Lewy body pathology in the brainstem. There was sparse Lewy pathology in the cortex. A striking finding was very pronounced ubiquitin-positive pathology in the brainstem, temporolimbic regions and neocortex. Ubiquitin positivity was most pronounced in the white matter, and was out of proportion to the comparatively weaker alpha-synuclein immunoreactivity. Immunostaining for tau was mildly positive, revealing non-specific changes, but staining for TDP-43 and FUS was entirely negative. The distribution and shape of ubiquitin-positive lesions in this patient differed from the few previously described patients with LRRK2 mutations and ubiquitin pathology, and the ubiquitinated protein substrate remains undefined.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154298      PMCID: PMC3330199          DOI: 10.1016/j.parkreldis.2011.11.019

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  21 in total

Review 1.  What genetics tells us about the causes and mechanisms of Parkinson's disease.

Authors:  Olga Corti; Suzanne Lesage; Alexis Brice
Journal:  Physiol Rev       Date:  2011-10       Impact factor: 37.312

2.  Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes.

Authors:  Kazuko Hasegawa; A Jon Stoessl; Teruo Yokoyama; Hisayuki Kowa; Zbigniew K Wszolek; Saburo Yagishita
Journal:  Parkinsonism Relat Disord       Date:  2008-09-18       Impact factor: 4.891

Review 3.  Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease.

Authors:  Isidre Ferrer; Anna Martinez; Rosa Blanco; Ester Dalfó; Margarita Carmona
Journal:  J Neural Transm (Vienna)       Date:  2010-09-23       Impact factor: 3.575

4.  Differential degeneration of the locus coeruleus in dementia subtypes.

Authors:  H Brunnström; N Friberg; E Lindberg; E Englund
Journal:  Clin Neuropathol       Date:  2011 May-Jun       Impact factor: 1.368

5.  Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions.

Authors:  Justus C Dächsel; Owen A Ross; Ignacio F Mata; Jennifer Kachergus; Mathias Toft; Ashley Cannon; Matt Baker; Jennifer Adamson; Mike Hutton; Dennis W Dickson; Matthew J Farrer
Journal:  Acta Neuropathol       Date:  2006-12-07       Impact factor: 17.088

6.  Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease.

Authors:  Jan O Aasly; Carles Vilariño-Güell; Justus C Dachsel; Philip J Webber; Andrew B West; Kristoffer Haugarvoll; Krisztina K Johansen; Mathias Toft; John G Nutt; Haydeh Payami; Jennifer M Kachergus; Sarah J Lincoln; Amela Felic; Christian Wider; Alexandra I Soto-Ortolaza; Stephanie A Cobb; Linda R White; Owen A Ross; Matthew J Farrer
Journal:  Mov Disord       Date:  2010-10-15       Impact factor: 10.338

Review 7.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.

Authors:  Dennis W Dickson; Heiko Braak; John E Duda; Charles Duyckaerts; Thomas Gasser; Glenda M Halliday; John Hardy; James B Leverenz; Kelly Del Tredici; Zbigniew K Wszolek; Irene Litvan
Journal:  Lancet Neurol       Date:  2009-12       Impact factor: 44.182

Review 8.  Neuropathology of non-motor features of Parkinson disease.

Authors:  Dennis W Dickson; Hiroshige Fujishiro; Carolyn Orr; Anthony DelleDonne; Keith A Josephs; Roberta Frigerio; Melinda Burnett; Joseph E Parisi; Kevin J Klos; J Eric Ahlskog
Journal:  Parkinsonism Relat Disord       Date:  2009-12       Impact factor: 4.891

9.  Non-motor features of Parkinson's disease: depression and dementia.

Authors:  Heinz Reichmann; Christine Schneider; Matthias Löhle
Journal:  Parkinsonism Relat Disord       Date:  2009-12       Impact factor: 4.891

10.  A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease.

Authors:  Valerie Voon; Paul Krack; Anthony E Lang; Andres M Lozano; Kathy Dujardin; Michael Schüpbach; James D'Ambrosia; Stephane Thobois; Filippo Tamma; Jan Herzog; Johannes D Speelman; Johan Samanta; Cynthia Kubu; Helene Rossignol; Yu-Yan Poon; Jean A Saint-Cyr; Claire Ardouin; Elena Moro
Journal:  Brain       Date:  2008-10       Impact factor: 13.501

View more
  17 in total

1.  Multisystem Lewy body disease and the other parkinsonian disorders.

Authors:  J William Langston; Birgitt Schüle; Linda Rees; R Jeremy Nichols; Carrolee Barlow
Journal:  Nat Genet       Date:  2015-12       Impact factor: 38.330

2.  Evidence for increased completed suicide in first-degree relatives of LRRK2 G2019S mutation Parkinson's disease.

Authors:  Roberto Angel Ortega; Mark Groves; Anat Mirelman; Roy N Alcalay; Deborah Raymond; Sonya Elango; Helen Mejia-Santana; Nir Giladi; Karen Marder; Susan B Bressman; Rachel Saunders-Pullman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-11-08       Impact factor: 10.154

Review 3.  Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Authors:  Iakov N Rudenko; Mark R Cookson
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 4.  Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.

Authors:  Susanne A Schneider; Roy N Alcalay
Journal:  Mov Disord       Date:  2017-11       Impact factor: 10.338

Review 5.  The neuropathology of genetic Parkinson's disease.

Authors:  Markos Poulopoulos; Oren A Levy; Roy N Alcalay
Journal:  Mov Disord       Date:  2012-03-26       Impact factor: 10.338

6.  The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2.

Authors:  Xiaorong Huang; Chunxiang Wu; Yangshin Park; Xuwei Long; Quyen Q Hoang; Jingling Liao
Journal:  FASEB J       Date:  2018-12-28       Impact factor: 5.191

Review 7.  Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells.

Authors:  Liesel Goveas; Eugénie Mutez; Marie-Christine Chartier-Harlin; Jean-Marc Taymans
Journal:  Cells       Date:  2021-04-22       Impact factor: 6.600

8.  Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo.

Authors:  Elena Kozina; Shankar Sadasivan; Yun Jiao; Yuchen Dou; Zhijun Ma; Haiyan Tan; Kiran Kodali; Timothy Shaw; Junmin Peng; Richard J Smeyne
Journal:  Brain       Date:  2018-06-01       Impact factor: 15.255

Review 9.  Cellular processes associated with LRRK2 function and dysfunction.

Authors:  Rebecca Wallings; Claudia Manzoni; Rina Bandopadhyay
Journal:  FEBS J       Date:  2015-05-09       Impact factor: 5.542

Review 10.  LRRK2: cause, risk, and mechanism.

Authors:  Coro Paisán-Ruiz; Patrick A Lewis; Andrew B Singleton
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.